CGTLive’s Weekly Rewind – October 7, 2022
Review top news and interview highlights from the week ending October 7, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. CardiAMP Cell Therapy Yields 100% Response Rate in Heart Failure
The new, 2-year data is from a roll-in cohort of 10 patients presented at the HFSA 2022 meeting.
2. CAR T Therapy Yields Remission in Systemic Lupus Erythematosus
Five patients with lupus treated with anti-CD19 CAR T-cell therapy are now in remission.
3. Christine Coughlin, MD, PhD, on TRACK-NK Technology in Non-Small Cell Lung Cancer
The chief executive officer of Cytoimmune discussed the company’s technology platforms and programs.
4. BioMarin Resubmits BLA for Hemophilia A Gene Therapy Val-Rox
A prior resubmission in June 2022 was delayed with requests for additional durability and safety data.
5. Samir Parekh, MD, on Investigating Treatment Options for Relapsed Myeloma
The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.
Enabling Wider Antigen Selection With Logic-Gated CAR T-Cell Therapy for Solid Tumors
November 25th 2023Maria Pia Morelli, MD, PhD, assistant professor, MD Anderson Cancer Center, discussed her work on the EVEREST-1 trial of logic-gated CAR T-cell therapy currently being evaluated in colorectal and pancreatic cancers.
